Month Year
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
Month Year
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
- Feb 7, 2022Company anticipates initiation of first part of pivotal study in the March-April 2022 timeframe
- Nov 22, 2021Patients who underwent the procedure, as part of the 2019 U.S. pilot study, were significantly more likely to recommend C-Scan test compared to colonoscopy
- Nov 2, 2021Patent valid through May 2034
-
Mar 19, 2021Received FDA IDE Approval for Pivotal Study of C-Scan®
- Mar 15, 2021Company expects to commence U.S. pivotal trial in late 2021
- Aug 6, 2020IDE submission to the FDA for C-Scan® planned for the end of 2020; Initiation of a U.S. pivotal study planned for 2021
- May 27, 2020Strengthened balance sheet through a total of $16.3 million in registered direct offerings and a private placement of ordinary shares in the first half of 2020